Company Overview

Update
Founded:
January, 2007
Headquarters:
Zürich
Funding:
$90.50M
Categories:
Biotechnology

Covagen develops protein-based therapeutics for the treatment of inflammatory diseases and cancer.

Description

Update

Covagen AG develops protein-based therapeutics for the treatment of inflammatory diseases and cancer. Its products enable the isolation of high affinity protein-based binders called Fynomers, which changes the activity of target molecules relevant in various diseases. Covagen AG was founded in 2007 and is based in Zürich, Switzerland.

Current Team (1)

Update

Board Members and Advisors (3)

Update

Funding Rounds (5) - $90.50M

Update

Investors (8)

Update

Offices/Locations (1)

Update
  • Office

    Y17 M22, Life Science ETH/Uni

    Winterthurerstrasse 190

    Zürich, 8057

    CHE

Images (1)

Update
  • 54132fc0bf6d2cfe3692174221bd1ece